Evaluation of Preoperative N1539 in Total Knee Arthroplasty

Inclusion Criteria: * Voluntarily provide written informed consent. * Be planned to undergo an elective, primary (no repeat arthroplasties) open unilateral total knee arthroplasty (TKA), and be expected to require IV analgesia, remain in an inpatient setting for ≥24 hours, and receive at least two doses of study drug. * ASA physical status category 1, 2, or 3. * Female subjects not pregnant or planning/attempting to become pregnant, not lactating; or commits to the use of an acceptable form of birth control for the duration of the study. * Have a body mass index \<40 kg/m\^2 Exclusion Criteria: * Have a known allergy or hypersensitivity to any study treatment. * Have a history of previous TKA. * Has plans for a concurrent surgical procedure (eg, bilateral TKA). * Has TKA planned to be performed under general anesthesia. * Have a history of myocardial infarction within the preceding 12 months. * Have, as determined by the investigator or the sponsor's medical monitor, a history or clinical manifestations of significant condition that would preclude participation. * Have active or recent (within 6 months) gastrointestinal ulceration or bleeding. * Have a known bleeding disorder which may be worsened with the administration of an NSAID. * Be currently receiving treatment with oral meloxicam (Mobic®) or another NSAID within 48 hours prior to surgery. * Have previously received N1539/IV meloxicam or received any investigational product within 30 days before dosing with study medication. * Have undergone or be expected to undergo radiation therapy, chemotherapy, or other biological therapy for cancer treatment, within 60 days prior to screening through last follow-up.